About Cannabinoid receptor 2
Cannabinoid receptor 2 (CNR2) is a protein
from Homo sapiens identified by UniProt accession
P34972, 360 residues long.
MolForge cross-references it against 0 known binders and
480 disease associations.
Target properties
| Protein name | Cannabinoid receptor 2 |
| UniProt accession | P34972 |
| Gene | CNR2 |
| Organism | Homo sapiens |
| Length | 360 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (480)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.37
- reticulocyte count · score 0.30
- eosinophil count · score 0.28
- reticulocyte measurement · score 0.24
- mean corpuscular volume · score 0.24
- mean corpuscular hemoglobin · score 0.24
- eosinophil percentage of leukocytes · score 0.23
- mean corpuscular hemoglobin concentration · score 0.22
- Immature Reticulocyte Fraction Measurement · score 0.22
- neurodegenerative disease · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P34972-F1 | alphafold | PREDICTED | 84.46 | — |
Amino-acid sequence (360 residues)
MEECWVTEIA NGSKDGLDSN PMKDYMILSG PQKTAVAVLC TLLGLLSALE NVAVLYLILS SHQLRRKPSY LFIGSLAGAD FLASVVFACS FVNFHVFHGV DSKAVFLLKI GSVTMTFTAS VGSLLLTAID RYLCLRYPPS YKALLTRGRA LVTLGIMWVL SALVSYLPLM GWTCCPRPCS ELFPLIPNDY LLSWLLFIAF LFSGIIYTYG HVLWKAHQHV ASLSGHQDRQ VPGMARMRLD VRLAKTLGLV LAVLLICWFP VLALMAHSLA TTLSDQVKKA FAFCSMLCLI NSMVNPVIYA LRSGEIRSSA HHCLAHWKKC VRGLGSEAKE EAPRSSVTET EADGKITPWP DSRDLDLSDC
Explore Cannabinoid receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets